Chapter 3: Pharmacodynamics — Module 8: Advanced Pharmacodynamic Concepts — Hysteresis, Indirect Response and Drug Interactions
1. A morphine infusion is started for a patient in severe cancer pain. The prescribing team notes that the patient's pain scores remain high for the first 30-45 minutes despite plasma morphine concentrations reaching target levels within 10 minutes of initiating the infusion. Which of the following best explains this temporal disconnect?
A) The delay reflects morphine's slow dissociation from plasma proteins -- at steady infusion rates, morphine remains protein-bound for 30-45 minutes before sufficient free drug is available to cross into the CNS and produce analgesia
B) The delay reflects the indirect response mechanism of opioid analgesia -- morphine does not directly inhibit pain signaling but suppresses prostaglandin synthesis, and the analgesia lag reflects the time required for existing prostaglandins to be cleared from nociceptive synapses after synthesis is inhibited
C) The delay reflects receptor desensitization occurring during the first 30-45 minutes of opioid receptor activation -- newly occupied mu-opioid receptors require GRK (G protein-coupled receptor kinase) phosphorylation and beta-arrestin binding before they can initiate the intracellular signaling cascade that produces analgesia
D) The delay reflects distributional lag from plasma to the CNS biophase -- morphine must cross the blood-brain barrier and equilibrate into the effect compartment (CNS) before producing its analgesic effect; morphine's relatively low lipophilicity compared to fentanyl means CNS equilibration is slow, with a ke0 (effect-site equilibration rate constant) that produces a plasma-to-biophase lag of approximately 15-30 minutes
E) The delay is a pharmacokinetic artifact -- the plasma concentrations measured at 30-45 minutes do not reflect true steady-state and are still rising; the apparent lag disappears when plasma concentrations are corrected for ongoing distribution into peripheral compartments
ANSWER: D
Rationale:
This question directly tests understanding of the effect compartment model and counterclockwise hysteresis. Morphine's analgesic effect is mediated through mu-opioid receptors in the CNS -- specifically in the periaqueductal gray, rostral ventromedial medulla, and spinal cord dorsal horn. To reach these sites, morphine must cross the blood-brain barrier. Morphine is more hydrophilic than most opioids -- particularly fentanyl, which crosses the BBB almost instantly -- and this relatively low lipophilicity means CNS equilibration is slow. The ke0 for morphine produces a biophase lag of approximately 15-30 minutes, consistent with the clinical observation that peak analgesic and respiratory depressant effects occur 15-30 minutes after peak plasma concentrations. This is the pharmacodynamic basis for the clinical teaching that IV morphine doses should not be repeated until at least 15-20 minutes have elapsed, to allow full CNS equilibration before assessing the need for redosing -- premature redosing can produce delayed respiratory depression as the first dose finally reaches the biophase.
Option A: Option A is incorrect -- morphine protein binding is approximately 35% and dissociation from plasma proteins is rapid; protein binding does not produce a 30-45 minute lag in CNS effect.
Option B: Option B is incorrect -- morphine does not produce analgesia through prostaglandin synthesis inhibition; that is acetaminophen and NSAIDs' mechanism; morphine acts directly on mu-opioid receptors.
Option C: Option C is incorrect -- GRK phosphorylation and beta-arrestin binding are part of the desensitization cascade that reduces receptor signaling over time; they do not delay the initiation of analgesia from a new agonist exposure.
Option E: Option E is incorrect -- while plasma concentrations do continue to distribute into peripheral compartments, the clinical lag in analgesia is a genuine pharmacodynamic distributional delay, not a measurement artifact.
2. Statins reduce LDL cholesterol substantially, but the maximum LDL-C reduction at a fixed dose is not achieved for 4-6 weeks after initiation. Which of the following correctly explains this time course using the indirect response model?
A) Statins inhibit HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, suppressing de novo cholesterol synthesis in the liver; the LDL-C pool in circulation is not directly removed by statins but must turn over through normal lipoprotein catabolism -- hepatic LDL receptor upregulation (in response to reduced intracellular cholesterol) increases LDL clearance from plasma, but the full reduction in the circulating LDL-C pool requires 4-6 weeks to manifest because LDL particles have a plasma half-life of approximately 2-3 days and the entire pool must turn over multiple times before the new lower steady state is reached
B) Statins require hepatic bioactivation by CYP3A4 to their active hydroxy acid form; the 4-6 week delay reflects the time required for progressive hepatic enzyme induction to reach steady-state bioactivation capacity, after which plasma statin concentrations stabilize and LDL-C reduction is maximal
C) Statins are direct inhibitors of LDL receptor recycling in hepatocytes -- their primary mechanism is slowing LDL receptor degradation rather than inhibiting cholesterol synthesis; the 4-6 week time course reflects the slow turnover of the hepatic LDL receptor pool under statin-mediated protection from degradation
D) The 4-6 week time to maximum LDL-C reduction is a pharmacokinetic phenomenon -- statins have a prolonged tissue half-life in hepatocytes due to active uptake by OATP1B1 (organic anion transporting polypeptide 1B1) transporters, and the 4-6 weeks reflects the time required for hepatic statin concentrations to reach steady state through progressive accumulation
E) Statins reduce LDL-C through an indirect mechanism involving intestinal bile acid sequestration -- statins inhibit hepatic bile acid synthesis, which reduces enterohepatic bile acid recirculation and increases fecal cholesterol excretion; the 4-6 week delay reflects the time required for the intestinal bile acid pool to be depleted sufficiently to alter cholesterol absorption
ANSWER: A
Rationale:
Statins are an excellent example of indirect pharmacodynamic response that involves inhibition of an endogenous production process. The direct effect of statin therapy is rapid: HMG-CoA reductase is inhibited within hours of the first dose, reducing hepatic de novo cholesterol synthesis. This reduction in intracellular hepatic cholesterol triggers upregulation of LDL receptors on hepatocyte surfaces, increasing the rate of LDL clearance from plasma. However, the circulating LDL-C pool does not disappear immediately -- it must turn over through normal lipoprotein catabolism. LDL particles have a plasma half-life of approximately 2-3 days, and the entire LDL-C pool requires multiple turnover cycles before the new lower steady state is established. This pool-depletion kinetics is why maximum LDL-C reduction takes 4-6 weeks despite the enzymatic effect being present from day one. This is the hallmark of indirect pharmacodynamic response: the time course of the pharmacological effect is determined not by the drug's pharmacokinetics but by the turnover kinetics of the biological system being modulated.
Option B: Option B is incorrect -- while some statins do require hepatic conversion (e.g., lovastatin, simvastatin are prodrugs), the 4-6 week delay is not due to CYP3A4 induction; the delay reflects LDL pool turnover, not statin bioactivation kinetics.
Option C: Option C is incorrect -- statins do not directly inhibit LDL receptor recycling; their mechanism is HMG-CoA reductase inhibition leading to secondary LDL receptor upregulation.
Option D: Option D is incorrect -- while hepatic statin uptake by OATP1B1 is pharmacokinetically important, statins reach hepatic steady-state concentrations within days, not 4-6 weeks; the delay is pharmacodynamic, not pharmacokinetic.
Option E: Option E is incorrect -- statins do not inhibit bile acid synthesis or function as bile acid sequestrants; that is the mechanism of cholestyramine and colesevelam.
3. A neonatal intensive care unit (NICU) physician is planning sedation for a procedure in a premature neonate. She explains to the team that neonates require lower weight-adjusted doses of benzodiazepines than older children, not simply because of immature hepatic metabolism but because of a pharmacodynamic difference. Which of the following correctly describes this pharmacodynamic difference?
A) Neonates have a lower density of GABA-A receptors than adults in all brain regions -- fewer receptors means less drug is required to achieve the same fractional receptor occupancy and therefore the same sedative effect
B) Neonatal GABA-A receptors are constitutively active at a higher baseline level than adult receptors -- the reduced benzodiazepine dose requirement reflects a lower threshold for reaching maximal GABAergic inhibition from an already elevated baseline
C) The neonatal blood-brain barrier is more permeable than in adults, allowing greater CNS drug penetration per unit of plasma drug concentration -- at a given plasma benzodiazepine concentration, the CNS biophase concentration is higher in neonates than in adults, producing greater pharmacodynamic effect
D) Neonates have immature hepatic glucuronidation but fully mature CYP3A4 activity -- the combination produces a unique metabolic profile in which benzodiazepines are converted to pharmacodynamically active glucuronide metabolites that accumulate and amplify the sedative effect
E) Neonates express a fetal isoform of the benzodiazepine binding site (alpha4-containing GABA-A receptors) that has higher affinity for benzodiazepines than the adult alpha1/alpha2-containing isoform -- the increased receptor affinity shifts the dose-response curve leftward, reducing the dose needed for equivalent sedation
ANSWER: C
Rationale:
The neonatal blood-brain barrier (BBB) is structurally and functionally immature compared to the adult BBB. The tight junctions between brain capillary endothelial cells are less developed, P-glycoprotein efflux transporter expression is lower, and the overall restrictive function of the BBB is reduced. The pharmacodynamic consequence is that for a given plasma drug concentration, the biophase (CNS) concentration is substantially higher in neonates than in adults -- more drug penetrates into the CNS per unit of plasma exposure. This means that neonates are more sensitive to CNS-active drugs at the level of CNS drug exposure, even if the pharmacodynamic response of the receptor itself were identical. Combined with immature hepatic metabolism (reduced clearance), neonates experience both higher plasma concentrations and greater CNS penetration per plasma concentration unit, producing marked sensitivity to benzodiazepines, opioids, and other CNS-active drugs. This is why neonatal dosing for CNS-active drugs must be substantially reduced compared to older children on a weight-adjusted basis.
Option A: Option A is incorrect -- GABA-A receptor density in the neonatal brain is not lower than in adults; in fact, neonatal CNS development involves high synaptic density; the sensitivity difference is not explained by fewer receptors.
Option B: Option B is incorrect -- neonatal GABA-A receptors are not constitutively active at higher baseline levels; the reduced dose requirement reflects drug distribution, not elevated baseline GABAergic tone.
Option D: Option D is incorrect -- neonatal CYP3A4 is actually immature, not fully mature; CYP3A4 activity is low at birth and increases postnatally; active glucuronide metabolite accumulation is not the mechanism of benzodiazepine sensitivity in neonates.
Option E: Option E is incorrect -- while GABA-A receptor subunit composition does differ between neonates and adults (with higher expression of alpha2/alpha3 subunits early in development), this does not produce the higher-affinity benzodiazepine binding site described; the primary pharmacodynamic explanation for neonatal sensitivity is BBB permeability, not receptor affinity.
4. A patient with advanced heart failure has beta1-adrenergic receptors that are markedly downregulated compared to a healthy individual. How does this receptor downregulation alter the pharmacodynamic parameters of the dose-response relationship for a beta-1 agonist such as dobutamine?
A) Both Emax and EC50 (concentration producing 50% of maximum effect) are unchanged in heart failure -- receptor downregulation affects only receptor reserve, and since receptor reserve is normally present, the same Emax and EC50 are maintained until receptor density falls below the reserve threshold
B) Emax is increased and EC50 is decreased in heart failure -- receptor downregulation produces compensatory upregulation of Gs protein coupling efficiency, amplifying the signal from each remaining receptor and shifting the dose-response curve upward and leftward
C) EC50 is markedly reduced and Emax is unchanged in heart failure -- the downregulated receptors are constitutively active and produce tonic signaling that effectively lowers the concentration of dobutamine needed to produce half-maximal effect
D) EC50 is unchanged but Emax is increased in heart failure -- downregulated receptors produce enhanced signal per receptor through Gs hypersensitization, maintaining EC50 while amplifying the maximum response achievable with dobutamine
E) Emax is reduced and EC50 may be increased -- with fewer functional beta1 receptors available, the maximum inotropic response achievable even at saturating dobutamine concentrations is lower than in a healthy heart; additionally, because receptor reserve is diminished or absent, higher dobutamine concentrations may be required to achieve half-maximal effect, shifting EC50 rightward
ANSWER: E
Rationale:
Beta1-adrenergic receptor downregulation in advanced heart failure is a well-characterized pharmacodynamic alteration that directly impairs the clinical response to inotropic agents. In the healthy heart, beta1 receptor density is sufficient to maintain a receptor reserve -- full inotropic response can be achieved at sub-saturating agonist concentrations because more receptors are available than the minimum required. Receptor reserve means that EC50 is lower than Kd, and Emax is maintained even when some receptors are occupied by antagonists. In advanced heart failure, beta1 receptor density falls by 50-70% through downregulation driven by chronic catecholamine excess. The consequences for dobutamine pharmacodynamics are twofold: first, Emax is reduced because fewer functional receptors are available to transduce the maximum signal, even at saturating dobutamine concentrations -- the maximum inotropic response is blunted. Second, receptor reserve is diminished or eliminated -- a higher proportion of available receptors must be occupied to produce half-maximal effect, which may shift EC50 rightward (increase the concentration required for half-maximal response). This is the pharmacodynamic basis for why dobutamine produces less inotropic effect in advanced heart failure than in normal hearts, and why doses must often be titrated upward.
Option A: Option A is incorrect -- receptor downregulation does reduce Emax once receptor reserve is exhausted; this is not preserved in advanced heart failure.
Option B: Option B is incorrect -- Gs protein coupling efficiency is also reduced in heart failure (uncoupling of beta receptors from Gs through GRK upregulation); there is no compensatory amplification.
Option C: Option C is incorrect -- downregulated receptors are not constitutively active; constitutive activity is a property of specific receptor mutations, not of downregulation.
Option D: Option D is incorrect -- Gs hypersensitization does not occur in heart failure; both receptor density and coupling efficiency are reduced.
5. The concept of Loewe additivity provides a reference framework for interpreting pharmacodynamic drug combinations. Using an isobologram, which of the following correctly identifies how synergism is distinguished from additivity?
A) Synergism is identified when the combination requires more of each drug than Loewe additivity predicts to achieve the same effect -- the isobologram curve bows outward (convex toward the origin), indicating that the drugs are less effective together than expected
B) Synergism is identified when the combination requires less of each drug than Loewe additivity predicts to achieve the same effect -- the isobologram curve bows inward (concave toward the origin, or "bowing in"), indicating that the drugs are more effective together than expected from simple additivity
C) Synergism is identified when the Emax of the combination exceeds the Emax of the more efficacious drug alone -- a synergistic combination can exceed the ceiling effect of either individual agent, which is the defining pharmacodynamic feature that distinguishes true synergism from additivity
D) The isobologram cannot distinguish synergism from additivity for drugs acting at the same receptor -- Loewe additivity assumes independent mechanisms, and for drugs at the same receptor, the Bliss independence model must be used instead
E) Synergism is identified when the EC50 of either drug is reduced in the presence of the other, regardless of whether the isobologram curve crosses the additive line -- a reduction in EC50 by any amount constitutes pharmacodynamic synergism by definition
ANSWER: B
Rationale:
The isobologram is the graphical method for distinguishing synergism, additivity, and antagonism in drug combinations. The isobol is a curve connecting all combinations of two drugs that produce the same specified effect (the isoeffective combinations). The Loewe additivity reference is a straight line connecting the doses of drug A alone and drug B alone that each produce the specified effect -- any combination lying on this straight line is additive (each drug contributes independently in proportion to its dose). Combinations lying below the additive line (closer to the origin) achieve the same effect with less of each drug than additivity predicts -- this concave (inward-bowing) isobologram indicates synergism. Combinations lying above the additive line (farther from the origin) require more of each drug than additivity predicts -- this convex (outward-bowing) isobologram indicates antagonism. The clinical and research importance of the isobologram is that it provides a rigorous quantitative framework for demonstrating synergism: it is not sufficient to observe that a combination works well; it must be shown that the combination achieves the same effect at lower doses than each drug alone would predict. TMP-SMX, antifungal combinations, and many cancer chemotherapy regimens have been validated as synergistic using isobolographic analysis.
Option A: Option A is incorrect -- the description of bowing outward and requiring more of each drug describes antagonism, not synergism; the directions are reversed.
Option C: Option C is incorrect -- synergism does not require exceeding the Emax of the more efficacious drug; synergism is defined by dose-sparing in achieving any specified effect, not by supramaximal responses.
Option D: Option D is incorrect -- Loewe additivity can be applied to drugs acting at the same receptor; the Bliss independence model is an alternative framework but not the required one for same-receptor combinations.
Option E: Option E is incorrect -- a reduction in EC50 of one drug in the presence of another is one pharmacodynamic indicator of synergism, but synergism is formally defined by isobolographic analysis as combinations requiring less than additive doses, not simply by EC50 reduction alone.
ANSWER KEY: Q1=D Q2=A Q3=C Q4=E Q5=B
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.